This business information is not released now.

This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.

CanBas Co., Ltd.
Pharmaceutical/Drug Discovery

last update:2017/8/25

Delegates :
Takumi Kawabe

Incorporated :
January  18 , 2000

Paid in Capital :
3400 Million yen  

Employees :
13 人

Address :
2-2-1 Otemachi, Numazu SHIZUOKA

+81-55-954-3666 / +81-954-3668


Attachment : [ 1.5MiB ]

Mission/Background :
CanBas was named after "cancer busters" to conquer cancer by a small group and "canvas" that is an image for the freedom of each and every person. Our mission is to conquer cancer. We are trying to find cure(s) for cancer patients based on our long experience in the bed side and laboratory. We established an excellent scientific advisory board in which Prof. Kufe at Dana Farber Cancer Institute, Prof. Von Hoff at Ariszona Cancer Center and TGen, and Prof. Dunphy at California Institute of Technology are in. Based on their excellent advice we are doing basic research, drug screening, chemical optimization, preclinical studies and clinical studies under US FDA IND.

Technology & Business
We have established a proprietary drug screening system which differenciate normal versus cancerous cells based on the cell cycle G2 checkpoint related phenotype. We obtained two major pipe lines by this method, CBP501 and CBS9106. CBP501 is a unique calmodulin modulator which increases platinum uptake of tumor cells specifically. It also suppresses tumor associated macrophases which leads to the suppression of metastasis, reduction of cancer stem cells, and augmention of tumor immunogenicity. CBS9106 is a XPO1/CRM1 inhibitor which leads to the accumulation of tumor suppressors in the nucleus in tumor cells and kill them.
Products & Service
Products & Service Name
Started a Phase Ib for triple drug combination, CBP501+CDDP+anti-PD1, in US
Find a partner
Licensed out world wide right, except Japan, China, Korea and Taiwan, to Stemline Therapeutics.
Finding a partner for the Asian rights including Japan.
Next generation peptide anti-cancer drug candidate
Find a partner to develop it.
IDO/TDO dual inhibitor
Close to identify best compound.
Find a partner to develop it.

WBC/CBP501 patent filed
3 poster presentations on additional function of CBP501 at AACR-NCI-EORTC meeting 2015 in Boston
2 papers published in Oncotarget on EMT suppression and macrophage suppression by CBP501.
Hot news
We have established and preclinically proved a molecular mechanism of action of CBP501 that led to the prolongation of overall survival in nin-small cell lung cancer patients in the global Phase II study.
Alliance strategy
Looking for partners for CBP501, CBP-A08, or IDO/TDO dual inhibitor.

This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.